Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease.
about
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study.Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis.Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4.Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone.Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease.Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis.Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns DiseasePeripheral blood neutrophil responses in children with shigellosis.Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease.Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis.Developments in the apheresis procedure for the treatment of inflammatory bowel disease.The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease.Neutrophil-dependent oxidative stress in ulcerative colitisCollagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease.The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.Cells, cytokines and inflammatory bowel disease: a clinical perspective.Current status and future perspectives of leukocytapheresis for inflammatory bowel disease.Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders.Therapeutic Apheresis in Pregnancy: Three Differential Indications With Positive Maternal and Fetal Outcome.Neutrophil Extracellular Traps in the Amniotic Cavity of Women with Intra-Amniotic Infection: A New Mechanism of Host Defense.Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation.Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study.Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study.Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice.Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
P2860
Q33626027-8D14307F-7D2D-4005-86D7-099B6D2EEA72Q33855532-D942470C-EF4B-438C-B071-F908A3E9770BQ33867970-4CB6AB95-C9FB-4DB0-BCB9-F9040ED681BEQ34008773-4A6DA47F-9C3F-4CB2-B91C-026C46E629DCQ34011689-F255C666-A618-4D98-9F9E-3D24542BD37BQ34410221-D677036C-1C32-4D95-84C9-D442966C6C63Q34604561-A7CE555D-D077-4948-9F1C-0ABEBF50B7FBQ34870365-7A5179C1-4287-4CCC-8AB5-60B1C6FDAD7DQ34958550-F0844B33-00BD-4408-B731-540D2B824A1CQ35010974-1991D6CC-2AD9-43D8-B884-6C2EA195BF2BQ35018662-F7814B66-C11F-497E-B0E1-F1CB2592A7C8Q35224927-8ECCC036-0FA5-4F0F-8B60-60661440122DQ36305774-B9555505-76CD-4FB2-BA85-769B7EFA6327Q36316681-0A0CC0C3-D9D1-4893-85BD-94B3216AC47FQ36353616-84247063-E143-40AD-97E0-EBB86424AAB1Q36446929-01B00358-7A37-4A11-A05B-C3970B8761F9Q36508776-F62CF2DB-4994-4161-B305-07138A3161FBQ37658664-FBF46C4F-4D2D-427A-BFD4-324F4F65A742Q37809574-4E5AD3BD-6CCB-4C28-BE55-99C30388A4EAQ37948155-CEE102D5-8575-4E04-8FED-33CE1517395FQ37993226-0B228428-6433-4842-8F15-F84B02427E0CQ38243723-BCED3A52-AF0B-42C8-8D29-C6CF3F79B2D7Q38895910-7BEA963A-07AC-4F59-BC9C-97D72888A60AQ40078827-E070805A-955E-477A-B3D1-1AADC2CE8C9FQ40467985-E51FABD9-980F-4E0D-9FB1-621DD19944B0Q42726307-3C606167-FB96-4135-921D-7337933F48CEQ43411685-F77620F7-B494-4768-BCA6-31B0876F9A3FQ43963773-ED224A70-398E-42B2-AB1C-1D41BACC1F11Q45056874-839FEF3B-2A29-45E5-B713-995DBFE051EFQ46821578-4B5F9456-0136-4845-86DD-4062B17491CAQ51247391-A19B05D6-FBE1-4CA3-AA9C-2C706ACD1FEEQ53117222-9DEC7887-824D-41AB-9708-482785530748Q53914270-2949B858-EEF3-4005-8EEA-72BB1EAE44DE
P2860
Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease.
description
1991 nî lūn-bûn
@nan
1991 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Peripheral blood neutrophils i ...... activation in active disease.
@ast
Peripheral blood neutrophils i ...... activation in active disease.
@en
type
label
Peripheral blood neutrophils i ...... activation in active disease.
@ast
Peripheral blood neutrophils i ...... activation in active disease.
@en
prefLabel
Peripheral blood neutrophils i ...... activation in active disease.
@ast
Peripheral blood neutrophils i ...... activation in active disease.
@en
P2093
P2860
P1476
Peripheral blood neutrophils i ...... activation in active disease.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.1991.TB02958.X
P577
1991-12-01T00:00:00Z